PROEHL GERALD T - 03 Jan 2022 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role
President, CEO and Chairman, Director, 10%+ Owner
Signature
/s/ Gerald T. Proehl Attorney-in-Fact
Issuer symbol
DRMA
Transactions as of
03 Jan 2022
Net transactions value
$0
Form type
4
Filing time
05 Jan 2022, 17:58:13 UTC
Previous filing
26 Nov 2021
Next filing
10 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRMA Stock Option (right to buy) Award $0 +197,610 $0.000000 197,610 03 Jan 2022 Common Stock 197,610 $1.88 Direct
transaction DRMA Stock Option (right to buy) Award $0 +4,517 $0.000000 4,517 03 Jan 2022 Common Stock 4,517 $2.07 Direct
transaction DRMA Stock Option (right to buy) Award $0 +42,141 $0.000000 42,141 03 Jan 2022 Common Stock 42,141 $2.07 Direct F1
transaction DRMA Stock Option (right to buy) Award $0 +57,859 $0.000000 57,859 03 Jan 2022 Common Stock 57,859 $1.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.